VAXCYTE INC

VAXCYTE’s New Director John Markels Exercises 23,029 Stock‑Option Shares, Stirring Investor Wariness Amid Strong Growth »

Dr. John Markels’ 23,029 stock‑option buy at VAXCYTE fuels board confidence yet sparks dilution concerns—watch the vesting schedule for the next move.

DirectorDealingsBot

16/07/2026, 23:12

2 minutes to read

CEO of Vaxcyte Buys 225 Shares Amid Day‑of‑Sales: Insider Activity Keeps Investors on Alert

Vaxcyte insider trades reveal routine portfolio moves, with CEO Pickering Grant buying 225 shares amid sales, suggesting balanced confidence in the biotech’s vaccine pipeline and future upside potential.

DirectorDealingsBot

19/06/2026, 02:23

4 minutes to read

VAXCYTE COO Executes 10b5‑1 Plan, Dumps 2,250 Shares Amid Broader Exec Sell‑Off — Liquidity Move, Not Loss of Faith?

Insightful VAXCYTE insider selling: COO’s 10b5‑1 sales reflect liquidity strategy, not confidence loss, amid a solid pipeline and market‑cap growth.

DirectorDealingsBot

03/06/2026, 23:19

3 minutes to read

Vaxcyte Exec Cowan Elvia Executes 3,000‑Share 10b5‑1 Plan, Buying at $25.92 and Selling at $60.00—A Signal of Steady Insider Confidence and Liquidity Management

Insider activity: Cowan Elvia’s disciplined 10b5‑1 buy/sell of Vaxcyte shares shows long‑term confidence in the vaccine pipeline and liquidity strategy.

DirectorDealingsBot

08/04/2026, 22:49

3 minutes to read

Vaxcyte SVP of Finance Executes Routine Rule‑Based Sale Amid Social‑Media Buzz—What Investors Should Know

Vaxcyte insider sale: Elvia Cowan’s Rule 10b5‑1 trades show routine liquidity, not distress—impact minimal on governance, stock stays steady.

DirectorDealingsBot

19/03/2026, 01:37

3 minutes to read

Vaxcyte’s Finance SVP Buys Record Shares as Insider Confidence Spurs Rally

Vaxcyte insider buying surge signals management confidence amid stock rally—find out why the finance SVP’s large purchase could boost vaccine‑stock prospects.

DirectorDealingsBot

03/03/2026, 02:24

4 minutes to read